Journal of Clinical Endocrinology & Metabolism, Vol 47, 461-464, Copyright © 1978 by Endocrine Society

ARTICLES

Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH

AA Kowarski, J Schneider, E Ben-Galim, VV Weldon and WH Daughaday

Two three-year-old boys with dwarfism (height ages 1-4/2 and 1-11/12 years) and delayed bone ages (1-4/12 and 1-9/12 years) had normal growth hormone (GH) responses after stimulation and low levels of somatomedin. Unlike patients with Laron syndrome, the two patients generated normal levels of somatomedin after administration of exogenous hGH. Treatment with hGH (2 IU every other day) brought about a significant increase in the growth rate of both patients. The growth rate of the first patient increased from 2 cm/year before treatment to 12 cm/year on therapy. The growth rate of the second patient was 4.5 cm/year before treatment, and 8.3 cm/year while on treatment. The two cases represent a new syndrome of dwarfism which may be caused by secretion of a biologically inactive but immunoreactive GH.

This article has been cited by other articles:

				P. E Mullis Genetic control of growth Eur. J. Endocrinol., January 1, 2005; 152(1): 11 - 31. [Abstract] [Full Text] [PDF]

				R. G. Rosenfeld and V. Hwa Toward a Molecular Basis for Idiopathic Short Stature J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1066 - 1067. [Full Text] [PDF]

				H. M. Domene, S. V. Bengolea, A. S. Martinez, M. G. Ropelato, P. Pennisi, P. Scaglia, J. J. Heinrich, and H. G. Jasper Deficiency of the Circulating Insulin-like Growth Factor System Associated with Inactivation of the Acid-Labile Subunit Gene N. Engl. J. Med., February 5, 2004; 350(6): 570 - 577. [Full Text] [PDF]

				M. Ishikawa, A. Nimura, R. Horikawa, N. Katsumata, O. Arisaka, M. Wada, M. Honjo, and T. Tanaka A Novel Specific Bioassay for Serum Human Growth Hormone J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4274 - 4279. [Abstract] [Full Text]

				A. Barreca, M. Bozzola, A. Cesarone, P. H. Steenbergh, P. E. Holthuizen, F. Severi, G. Giordano, and F. Minuto Short Stature Associated with High Circulating Insulin-Like Growth Factor (IGF)-Binding Protein-1 and Low Circulating IGF-II: Effect of Growth Hormone Therapy J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3534 - 3541. [Abstract] [Full Text]

				C. L. Boguszewski, C. Jansson, M. C. S. Boguszewski, S. Rosberg, B. Carlsson, K. Albertsson-Wikland, and L. M. S. Carlsson Increased Proportion of Circulating Non-22-Kilodalton Growth Hormone Isoforms in Short Children: A Possible Mechanism for Growth Failure J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2944 - 2949. [Abstract] [Full Text] [PDF]

				Y. Takahashi, H. Kaji, Y. Okimura, K. Goji, H. Abe, and K. Chihara Short Stature Caused by a Mutant Growth Hormone N. Engl. J. Med., February 15, 1996; 334(7): 432 - 436. [Full Text] [PDF]